by emma
29. July 2011 13:14
Genzyme and Isis Pharmaceuticals have submitted a marketing authorisation application to the EMA for the approval of Kynamro (mipomersen) to treat homozygous and severe heterozygous familial hypercholesterolemia.
Kynamro is a first-in-class apo-B synthesis inhibitor currently in late-stage development for the reduction of LDL cholesterol (LDL-C).
Paula Soteropoulos, Vice President and General Manager of Genzyme’s Cardiovascular Business, says the submission is a “significant step in the development of mipomersen”.
The US regulatory submission of inhibitor is now planned for later this year.
Familial hypercholesterolemia is a genetic disease that results in increased LDL-C levels and can lead to premature heart disease and heart disease-related death.
Patients with severe familiar hypercholesterolemia have cholesterol levels two-to-four times higher than recommended levels, even when taking multiple cholesterol-lowering medication.
“Mipomersen has the potential to change the management of patients with homozygous and severe heterozygous familial hypercholesterolemia,” said Stanley Crook, Chairman and CEO of Isis Pharmaceuticals.
90db937a-8f79-48dd-a61d-043782cb36a2|0|.0
Tags: homozygous, familial hypercholesterolaemia, Kynamro, application, apo-B, product news, synthesis, inhibitor, pharma, LDL-C, pharmaceuticals, LDL cholesterol, Genzyme, Paula Soteropoulos, Isis Pharmaceuticals, genetic disease, EMA, heart disease, mipomersen, medication, homozygous, familial hypercholesterolaemia, Stanley Crook, apo-B, synthesis, inhibitor, LDL-C, LDL cholesterol, Paula Soteropoulos, genetic disease, heart disease, medication, Stanley Crook
News
Subscribe